|
1.Pang X, Zhang J, He X, Gu Y, Qian BZ, Xie R, Yu W, Zhang X, Li T, Shi X, Zhou Y, Cui Y. SPP1 Promotes Enzalutamide Resistance and
Epithelial-Mesenchymal-Transition Activation in Castration-Resistant Prostate Cancer via PI3K/AKT and ERK1/2 Pathways.
Oxid Med Cell Longev. 2021 Oct 22;2021:5806602. (Q2, IF=6.543)
2.Kang X, Zheng X, Xu D, Su T, Zhou Y, Ji J, Yu Q, Cui Y, Yang L. A cross-sectional study of chemotherapy-related AKI. Eur J Clin Pharmacol.
2021 Oct;77(10):1503-1512. (Q3, IF=2.953)
3.Zhang E, Tian X, Li R, Chen C, Li M, Ma L, Wei R, Zhou Y, Cui Y. Dalfampridine in the treatment of multiple sclerosis: a meta-analysis of
randomised controlled trials. Orphanet J Rare Dis. 2021 Feb 15;16(1):87. (Q2, IF=4.123)
4.Cui Y, Zhu C, Lian Z, Han X, Xiang Q, Liu Z, Zhou Y. Prospective association between depressive symptoms and stroke risk among middle-aged
and older Chinese. BMC Psychiatry. 2021 Oct 27;21(1):532. (Q2, IF=3.630)
5.Gong J, Ma L, Li M, Ma L, Chen C, Zhao S, Zhou Y, Cui Y. Nonsteroidal anti-inflammatory drugs associated acute kidney injury in hospitalized children:
A systematic review and meta-analysis. Pharmacoepidemiol Drug Saf. 2022 Feb;31(2):117-127. (Q2, IF=2.890)
6.Zhang E, Wu Y, Chen C, Wei R, Zhang J, Xie H, Wei C, Ma L, Dong X, Li R, Zhou Y, Cui Y, Wu Y. Effect of different initial rituximab
regimens on B cell depletion in children with autoimmune neurological diseases. Mult Scler Relat Disord. 2022 Jan 29;59:103510. (Q2, IF=4.339)
7.李若茗,解染,田欣,董秀,陈超阳,马凌云,刘晓,周颖,崔一民.托法替布治疗类风湿关节炎的快速卫生技术评估[J].中国新药杂志,2021,30(05):462-469.
8.李敏,马凌云,陈超阳,周颖,杨艳玲,崔一民.丙酮酸钠药理学作用的研究现状[J].中国临床药理学杂志,2021,37(03):341-344.
|
